LEADER 04184nam  22004575  450 
001 9910298422703321
005 20200701213226.0
010   $a981-10-7506-9
024 7 $a10.1007/978-981-10-7506-3
035   $a(CKB)3850000000034237
035   $a(MiAaPQ)EBC5448151
035   $a(DE-He213)978-981-10-7506-3
035   $a(PPN)229499759
035   $a(EXLCZ)993850000000034237
100   $a20180702d2018      u|         0
101 0 $aeng
135   $aurcnu||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 10$aGenomics-Driven Healthcare $eTrends in Disease Prevention and Treatment /$fedited by Yashwant Pathak
205   $a1st ed. 2018.
210  1$aSingapore :$cSpringer Singapore :$cImprint: Adis,$d2018.
215   $a1 online resource (413 pages)
311   $a981-10-7505-0 
327   $aChapter 1. Rethinking drug discovery and targeting after the genomic revolution -- Chapter 2. Living between sickness and health: Where is the human genome leading us? -- Chapter 3. Pharmacogenomics: Setting Newer Paradigms of Genetics in Therapy and Medicine -- Chapter 4. Bioinformatics and Pharmacogenomics: Tools to Understand and Accelerate Infectious Disease Control -- Chapter 5. Race and Ethnicity ? Understanding Difference in the Genome Era -- Chapter 6. The Food Metabolome and Novel Dietary Biomarkers Associated with Diseases -- Chapter 7. Impact of genomics on drug discovery and clinical medicine -- Chapter 8. Genomics and drug transporters and application in drug discovery, delivery and development -- Chapter 9. Genomics and drug metabolizing enzymes its application in Drug delivery: Evaluating the influence of the microbiome -- Chapter 10. Essentials of Genomics in the Continuum of Translational Research -- Chapter 11. Charting a course for genomic medicine from base pair to bedside -- Chapter 12. Pharmacogenomics and pharmacoepigenomics: impact on therapeutic strategies -- Chapter 13. Clinical Pharmacogenomics and Personalized Medicine: New strategies to maximize drug efficacy and avoid adverse drug reaction -- Chapter 14. Epigenetic Patterns/Therapies associated with Genetic Disorders -- Chapter 15. Neurodegenerative disease conditions and genomic treatment for better health -- Chapter 16. Recent Trends in -Omics based methods and techniques for Lung Diseases prevention -- Chapter 17. Impact of Genomics on Personalization of Breast Cancer Care -- Chapter 18. Pharmacogenomics: a new approach for preventing severe cutaneous adverse drug reactions.
330   $aThis book evaluates trends arising in ?-Omics? sciences in terms of their current and potential future application to therapeutic design and understanding of disease. Chapters consider the impact of pharmacogenomics and bioinformatics on drug development, as well as trends in genomics, as applied to understanding of neurodegenerative and lung disease, psychiatry and oncology. Following the genome studies released in early part of this century, the advent of the -Omics sciences (genomics and pharmacogenomics, proteomics, metabolomics, transcriptomics) has seen the expansion of a vast knowledgebase with utility in preventing and treating disease, and improving health for all. Bioinformatics and improved pharmacogenetic understanding forge a path for improved drug discovery and design methods accounting for differences in delivery and disposition across populations.
606   $aPharmaceutical technology
606   $aHealth promotion
606   $aPharmaceutical Sciences/Technology$3https://scigraph.springernature.com/ontologies/product-market-codes/B21010
606   $aHealth Promotion and Disease Prevention$3https://scigraph.springernature.com/ontologies/product-market-codes/H27010
615  0$aPharmaceutical technology.
615  0$aHealth promotion.
615 14$aPharmaceutical Sciences/Technology.
615 24$aHealth Promotion and Disease Prevention.
676   $a615.7
702   $aPathak$b Yashwant$4edt$4http://id.loc.gov/vocabulary/relators/edt
906   $aBOOK
912   $a9910298422703321
996   $aGenomics-Driven Healthcare$92521379
997   $aUNINA